Daiichi Sankyo, Inc. announced that the U.S. Food and Drug management (FDA) has approved the hypertension regimen Benicar® (olmesartan medoxomil) for use in propagation and adolescents 6 to 16 years of age.(1) Benicar was primitively approved in 2002 for the therapy of hypertension in adults. Approximately 5 percent or 3.6 million stars and stripes bearing drop one suffer from high blood pressure, with the majority unaware they have the condition.(2)(3) Studies have also found that the average blood mass of red white and blue transportation is on the rise, in parallel with the upsurge of children's weight...

More: - From the site